An Experience with Disulfiram in the management of Alcohol Dependence Syndrome

Introduction Disulfiram is a medication that raises blood acetaldehyde levels by inhibiting aldehyde dehydrogenase. It has been reported that taking disulfiram can cause psychosis or mania. There are only a few case reports in the literature, mostly about mania. We introduce this case of disulfiram-induced mania without dose adjustment whereas continuing maintenance treatment at the prescribed amount in a patient with no psychiatric history. Case Mr. K, a 57-year-old patient with a history of 25 years of alcohol consumption, had stopped drinking five months ago and had been taking disulfiram (500 mg/day) for five months. During treatment, he was admitted to the outpatient clinic with complaints of decreased need for sleep, increased speech, and psychomotor activity, — in particular for 4-5 days. During the psychiatric examination, it was discovered that the rate of speech had increased, that flight of ideas was present, and that the affect was cheerful and nervous. There was an increase in self-esteem and grandiose delusion. The examination revealed psychomotor agitation. The patient was admitted to the hospital for examination, follow-up, and treatment. Mania was observed. Treatment with valproate 1000 mg/day and risperidone 4 mg/day was planned. The patient showed no psychotic or manic symptoms while continuing outpatient clinic controls. Conclusion Rare complications, such as manic episodes, might occur even in patients receiving the prescribed amount and long-term disulfiram treatment.

show abstract

An Experience with Disulfiram in the management of Alcohol Dependence Syndrome

Cited by 5 publications

References 1 publication

Manic Episode With Psychotic Symptoms Associated With High Dose of Disulfiram

Manic Episode With Psychotic Symptoms Associated With High Dose of Disulfiram

The implications of medication development in the treatment of substance use disorders in developing countries

Mania as a result of using disulfiram at the prescribed amount during the fifth month of maintenance therapy: a casa report

Contact Info

Product

Resources

About